Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Primary Immunodeficiency (PID) Clinical Trial

Official title:
A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (IgPro20 EU Extension Study)

Status Completed

Clinical Trial Summary

This study is a continuation of the study ZLB06_001CR with the objective of assessing efficacy, tolerability, safety of IgPro, as well as long-term health-related quality of life in patients with PID.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00751621
Study type	Interventional
Source	CSL Behring
Contact
Status	Completed
Phase	Phase 3
Start date	August 2008
Completion date	December 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01287689` - Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study	N/A
Recruiting	`NCT01962415` - Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT	Phase 2
Recruiting	`NCT04528355` - Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
Completed	`NCT02180763` - Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps	Phase 4
Completed	`NCT00391131` - Subcutaneous Ig NextGen 16% in PID Patients	Phase 3